Methotrexate
Orphan DrugFDA Approved
Description
Methotrexate is an antimetabolite and antifolate drug used in the treatment of gestational trophoblastic neoplasms including choriocarcinoma and hydatidiform mole. It inhibits dihydrofolate reductase, preventing DNA synthesis in rapidly dividing cells. Methotrexate has been a cornerstone of treatment for low-risk gestational trophoblastic disease for decades.
Indications & Therapeutic Use
Gestational trophoblastic neoplasm, choriocarcinoma, hydatidiform mole, rheumatoid arthritis, psoriasis
Global Availability (9 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Methotrexate
| Generic Name | Methotrexate |
| Brands | 1 brand available |
| Active Ingredient | Methotrexate |
| Drug Class | Gestational trophoblastic neoplasm |
| Manufacturer | Multiple manufacturers |
| Dosage Forms | Oral tablet 2.5mg, 5mg, 7.5mg, 10mg, 15mg; Injectable solution 25mg/mL |
| Medical Code | L01BA01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 3 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00339235 |
| Countries | 9 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations10 Validated Nodes